Abstract:Degeneration of basal forebrain cholinergic neurons (BFCNs) in the nucleus basalis of Meynert (NBM) and vertical diagonal band (VDB) along with their connections is a key pathological event leading to memory impairment in Alzheimer's disease (AD). Aberrant neurotrophin signaling via Trks and the p75 neurotrophin receptor (p75NTR) contributes importantly to BFCN dystrophy. While NGF/TrkA signaling has received the most attention in this regard, TrkB and TrkC signaling also provide trophic support to BFCNs and these receptors may be well located to preserve BFCN connectivity. We previously identified a small molecule TrkB/TrkC ligand, LM22B-10, that promotes cell survival and neurite outgrowth in vitro and activates TrkB/TrkC signaling in the hippocampus of aged mice when given intranasally, but shows poor oral bioavailability. An LM22B-10 derivative, PTX-BD10-2, with improved oral bioavailability has been developed and this study examined its effects on BFCN atrophy in the hAPPLond/Swe (APPL/S) AD mouse model. Oral delivery of PTX-BD10-2 was started after appreciable amyloid and cholinergic pathology was present to parallel the clinical context, as most AD patients start treatment at advanced pathological stages. PTX-BD10-2 restored cholinergic neurite integrity in the NBM and VDB, and reduced NBM neuronal atrophy in symptomatic APPL/S mice. Dystrophy of cholinergic neurites in BF target regions, including the cortex, hippocampus, and amygdala, was also reduced with treatment. Finally, PTX-BD10-2 reduced NBM tau pathology and improved the survival of cholinergic neurons derived from human induced pluripotent stem cells (iPSCs) after amyloid-β exposure. These data provide evidence that targeting TrkB and TrkC signaling with PTX-BD10-2 may be an effective disease-modifying strategy for combating cholinergic dysfunction in AD. The potential for clinical translation is further supported by the compound's reduction of AD-related degenerative processes that have progressed beyond early stages and its neuroprotective effects in human iPSC-derived cholinergic neurons.

O2‐12‐04: Extracellular Domain of P75ntr Attenuates Beta‐amyloid‐induced Neurotoxicity and Tau Hyperphosphorylation

P75ntr Regulates Aβ Deposition by Increasing Aβ Production but Inhibiting Aβ Aggregation with Its Extracellular Domain

P4‐070: Roles of P75ntr in APP Trafficking and Processing

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies

P75 Neurotrophin Receptor Interacts with and Promotes BACE1 Localization in Endosomes Aggravating Amyloidogenesis.

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

p75NTR Ectodomain Ameliorates Cognitive Deficits and Pathologies in a Rapid Eye Movement Sleep Deprivation Mice Model

Involvement of P75ntr in the Effects of Aβ on L-type Ca2+ Channel in Cultured Neuronal Networks

Protective Effects Of Erythropoietin On Tau Phosphorylation Induced By Beta-Amyloid

Inhibition of Alzheimer’s Amyloid Toxicity with a Tricyclic Pyrone Molecule in Vitro and in Vivo

Trilobatin Protects Against Aβ25–35-Induced Hippocampal HT22 Cells Apoptosis Through Mediating ROS/p38/Caspase 3-Dependent Pathway

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Triptolide Attenuated Injury Via Inhibiting Oxidative Stress in Amyloid-Beta25–35-treated Differentiated PC12 Cells

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

p75ECD-Fc reverses neonatal hypoxic-ischemic encephalopathy-induced neurological deficits and inhibits apoptosis associated with Nestin

p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro.

Erythropoietin Prevents PC12 Cells from Beta-Amyloid-induced Apoptosis Via PI3K⁄Akt Pathway

Altered Expression of Neurotrophin Receptor P75 NTR in PrP106-126-induced Neurotoxicity of N2a Cells

Interaction Between TRPML1 and P62 in Regulating Autophagosome-Lysosome Fusion and Impeding Neuroaxonal Dystrophy in Alzheimer’s Disease

The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau

Small molecule modulation of TrkB and TrkC neurotrophin receptors prevents cholinergic neuron atrophy in an Alzheimer's disease mouse model at an advanced pathological stage